Franco Lori

Summary

Country: Italy

Publications

  1. ncbi Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells
    J Lisziewicz
    Research Institute for Genetic and Human Therapy RIGHT, Washington, DC 20007, USA
    J Virol 75:7621-8. 2001
  2. ncbi Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns
    Julianna Lisziewicz
    Research Institute for Genetic and Human Therapy, Washington DC 20007, USA
    Drug Saf 26:605-24. 2003
  3. ncbi Immune reconstitution and control of HIV
    Franco Lori
    The Research Institute for Genetic and Human Therapy, Policlinico San Matteo, Piazzale Golgi 2, 27100 Pavia, Italy
    HIV Clin Trials 5:170-82. 2004
  4. ncbi DermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS
    Franco Lori
    ViroStatics srl, Viale Umberto I, 07100, Sassari, Italy
    Expert Rev Vaccines 10:1371-84. 2011
  5. ncbi "Virostatics" as a potential new class of HIV drugs
    L M Kelly
    Research Institute for Genetic and Human Therapy RIGHT, 2233 Wisconsin Ave Suite 503, Washington, DC 20007, USA
    Curr Pharm Des 10:4103-20. 2004
  6. ncbi DermaVir, a novel HIV immunisation technology
    Franco Lori
    Research Institute for Genetic and Human Therapy, 2233 Wisconsin Ave Suite 503, Washington, DC 20007, USA
    Vaccine 23:2030-4. 2005
  7. ncbi Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency
    Franco Lori
    Research Institute for Genetic and Human Therapy RIGHT, IRCCS Policlinico S Matteo, 27100 Pavia, Italy
    AIDS Res Hum Retroviruses 21:263-72. 2005
  8. ncbi Cytokine-adjuvanted HIV-DNA vaccination strategies
    Franco Lori
    Research Institute for Genetic and Human Therapy RIGHT, Pavia, Italy
    Springer Semin Immunopathol 28:231-8. 2006
  9. ncbi Virostatics: a new class of anti-HIV drugs
    F Lori
    RIGHT Research Institute for Genetic and Human Therapy, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
    Curr Med Chem 14:233-41. 2007
  10. ncbi Immunological approaches for HIV therapy
    F Lori
    Research Institute for Genetic and Human Therapy, at IRCCS Policlinico S Matteo, Pavia, Italy
    Curr Drug Targets Infect Disord 3:171-8. 2003

Collaborators

Detail Information

Publications37

  1. ncbi Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells
    J Lisziewicz
    Research Institute for Genetic and Human Therapy RIGHT, Washington, DC 20007, USA
    J Virol 75:7621-8. 2001
    ..Successful induction of a broad and long-lasting HIV-specific cellular immunity is expected to control virus replication in infected individuals...
  2. ncbi Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns
    Julianna Lisziewicz
    Research Institute for Genetic and Human Therapy, Washington DC 20007, USA
    Drug Saf 26:605-24. 2003
    ..While the combination of hydroxyurea with didanosine has provided hope, future studies including those that evaluate optimal dosing and long-term toxicity are needed to define the role for this agent in the treatment of HIV infection...
  3. ncbi Immune reconstitution and control of HIV
    Franco Lori
    The Research Institute for Genetic and Human Therapy, Policlinico San Matteo, Piazzale Golgi 2, 27100 Pavia, Italy
    HIV Clin Trials 5:170-82. 2004
  4. ncbi DermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS
    Franco Lori
    ViroStatics srl, Viale Umberto I, 07100, Sassari, Italy
    Expert Rev Vaccines 10:1371-84. 2011
    ..The DermaVir technology platform for dendritic cell-based therapeutic vaccination might offer a new treatment paradigm for cancer and infectious diseases...
  5. ncbi "Virostatics" as a potential new class of HIV drugs
    L M Kelly
    Research Institute for Genetic and Human Therapy RIGHT, 2233 Wisconsin Ave Suite 503, Washington, DC 20007, USA
    Curr Pharm Des 10:4103-20. 2004
    ..The rationale for the use of virostatics in HIV/AIDS, their mechanism of action, and ongoing preclinical and clinical research will be reviewed...
  6. ncbi DermaVir, a novel HIV immunisation technology
    Franco Lori
    Research Institute for Genetic and Human Therapy, 2233 Wisconsin Ave Suite 503, Washington, DC 20007, USA
    Vaccine 23:2030-4. 2005
    ..DermaVir is a promising antiretroviral treatment approach with a unique mechanism of action for combination with currently used drugs...
  7. ncbi Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency
    Franco Lori
    Research Institute for Genetic and Human Therapy RIGHT, IRCCS Policlinico S Matteo, 27100 Pavia, Italy
    AIDS Res Hum Retroviruses 21:263-72. 2005
    ..At the optimal dosage of 600 mg daily, hydroxyurea, in combination with didanosine, deserves reevaluation for the long-term management of HIV/AIDS worldwide, because of its excellent resistance profile, durability, and affordability...
  8. ncbi Cytokine-adjuvanted HIV-DNA vaccination strategies
    Franco Lori
    Research Institute for Genetic and Human Therapy RIGHT, Pavia, Italy
    Springer Semin Immunopathol 28:231-8. 2006
    ....
  9. ncbi Virostatics: a new class of anti-HIV drugs
    F Lori
    RIGHT Research Institute for Genetic and Human Therapy, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
    Curr Med Chem 14:233-41. 2007
    ..e. toxicity and reasons for prescribing a perceived immune suppressant to immune compromised patients...
  10. ncbi Immunological approaches for HIV therapy
    F Lori
    Research Institute for Genetic and Human Therapy, at IRCCS Policlinico S Matteo, Pavia, Italy
    Curr Drug Targets Infect Disord 3:171-8. 2003
    ..DermaVir is the first topical vaccine, in combination with antiretroviral therapy, to demonstrate immunological and clinical benefits in a relevant animal model (chronically infected rhesus macaques)...
  11. ncbi Structured treatment interruptions for the management of HIV infection
    F Lori
    Research Institute for Genetic and Human Therapy, Washington, DC, USA
    JAMA 286:2981-7. 2001
    ..Ultimately, a safer approach using therapeutic immunization or vaccination would be preferable for stimulating vigorous T-cell-mediated immune responses and control of HIV during treatment interruption...
  12. ncbi Structured treatment interruptions in HIV/AIDS therapy
    Julianna Lisziewicz
    Research Institute for Genetic and Human Therapy, IRCCS Policlinico S Matteo, P le Golgi, 2 27100, Pavia, Italy
    Microbes Infect 4:207-14. 2002
    ..The potential costs and benefits of STI should be determined...
  13. ncbi Gene therapy approaches to HIV infection
    Franco Lori
    Research Institute for Genetic and Human Therapy at IRCCS Policlinico S Matteo, Pavia, Italy
    Am J Pharmacogenomics 2:245-52. 2002
    ..Since the immune system can significantly amplify the response to tiny amounts of antigen, DNA vaccines can indeed be delivered by exploiting traditional gene therapy approaches without the need of high transduction efficiency...
  14. ncbi Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses
    Franco Lori
    Research Institute for Genetic and Human Therapy RIGHT at IRCCS Policlinico S Matteo, Pavia, Italy
    HIV Clin Trials 3:115-24. 2002
    ..To study whether and under what circumstances HIV can be controlled in chronically infected patients...
  15. ncbi Structured treatment interruptions as a potential alternative therapeutic regimen for HIV-infected patients: a review of recent clinical data and future prospects
    Franco Lori
    Research Institute for Genetic and Human Therapy at IRCCS Policlinico S Matteo, P le Golgi, 2 27100 Pavia, Italy
    J Antimicrob Chemother 50:155-60. 2002
    ..Therefore, clinicians and patients should avoid using STI outside the setting of controlled clinical trials...
  16. ncbi Control of viral rebound through therapeutic immunization with DermaVir
    Julianna Lisziewicz
    Research Institute for Genetic and Human Therapy, Washington, DC 20007, USA
    AIDS 19:35-43. 2005
    ..To reconstitute immune responses capable of eliminating infected cells and suppressing viral load during chronic retroviral infection...
  17. ncbi HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals
    Sandra A Calarota
    Research Institute for Genetic and Human Therapy, Fondazione Istituto de Ricovero e Cura a Carattere Scientifico, Policlinoco San Matteo, Piazzale Golgi 2, Pavia, Italy
    J Immunol 180:5907-15. 2008
    ..The PHPC assay might be an attractive option for individual patient management and for the design and testing of therapeutic and prophylactic vaccines...
  18. ncbi Hydroxyurea exerts a cytostatic but not immunosuppressive effect on T lymphocytes
    Luca Lova
    Research Institute for Genetic and Human Therapy at IRCCS Policlinico S. Matteo, Pavia, Italy
    AIDS 19:137-44. 2005
    ..The increase in cytokine production at the single cell level might compensate for the decrease in the percentage of activated CD4 T lymphocytes, without overall impairment of HIV-specific immune responses...
  19. ncbi Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions
    Andrea Foli
    RIGHT at IRCCS Policlinico S Matteo, Pavia, Italy
    Antivir Ther 9:123-32. 2004
    ....
  20. ncbi IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine
    Sandra A Calarota
    Research Institute for Genetic and Human Therapy RIGHT, 27100 Pavia, Italy
    Vaccine 26:5188-95. 2008
    ..Our study demonstrates that IL-15 is more potent than IL-7 in enhancing HIV-1-specific central memory T-cells induced by topical DermaVir. IL-15 adjuvanted DermaVir might be an alternative prime in a prophylactic vaccine regimen...
  21. ncbi Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms
    Franco Lori
    Research Institute for Genetic and Human Therapy, IRCCS Policlinico S. Matteo, Pavia, Italy and Washington, DC 2007, USA
    AIDS 19:1173-81. 2005
    ....
  22. ncbi Effects of structured treatment interruptions on metabolic, anthropometric, immunologic, and quality of life outcomes in HIV-positive adults on HAART
    Renato Maserati
    HIV AIDS Outpatient Clinic, Infectious Disease Dept, at Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
    Curr HIV Res 5:337-43. 2007
    ..Cyclic structured treatment interruptions may have a favorable, although limited, impact on plasma total cholesterol levels in HIV-infected subjects. No modifications of anthropometric and quality of life values were noted...
  23. ncbi Induction of HIV-specific memory T-cell responses by topical DermaVir vaccine
    Sandra A Calarota
    Research Institute for Genetic and Human Therapy RIGHT, 4400 East West Hwy, Suite 1126, Bethesda, MD 20814, USA
    Vaccine 25:3070-4. 2007
    ..DermaVir formulation combined with topical administration provides an improved immunogenicity of antigen-expressing DNA vaccines...
  24. ncbi DermaVir: a novel topical vaccine for HIV/AIDS
    Julianna Lisziewicz
    Research Institute for Genetic and Human Therapy RIGHT, Washington, DC 20007, USA
    J Invest Dermatol 124:160-9. 2005
    ..Topical DermaVir vaccination represents an improvement upon existing ex vivo DC-based immunization technologies and may provide a new therapeutic option for HIV-infected patients...
  25. ncbi Topical DermaVir vaccine targeting dendritic cells
    Julianna Lisziewicz
    Research Institute for Genetic and Human Therapy RIGHT, Washington, DC, USA
    Curr Drug Deliv 3:83-8. 2006
    ..DermaVir represents a potential new approach for the treatment of HIV infection to be utilized either in conjunction with antiretroviral therapy or during structured treatment interruption...
  26. ncbi Methods of using interleukin 2 to enhance HIV-specific immune responses
    Jianqing Xu
    Research Institute for Genetic and Human Therapy (RIGHT, Washington, DC 20007, USA
    AIDS Res Hum Retroviruses 18:289-93. 2002
    ..Therefore, a combination of IL-2 with either structured treatment interruption, which results in a controlled viral load rebound, or with therapeutic vaccination is expected to improve HIV-specific T cell-mediated immune responses...
  27. ncbi A checkpoint in the cell cycle progression as a therapeutic target to inhibit HIV replication
    Andrea Foli
    Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy
    J Infect Dis 196:1409-15. 2007
    ..These results identify a specific phase of the cell cycle progression that is critical for HIV expression and suggest a new discrete target for anti-HIV treatment...
  28. ncbi Safety of hydroxyurea in the treatment of HIV infection
    Franco Lori
    Research Institute for Genetic and Human Therapy (RIGHT) at IRCCS Policlinico S. Matteo, Pavia, Italy
    Expert Opin Drug Saf 3:279-88. 2004
    ..This review critically examines the role of hydroxyurea for HIV-infected patients, focusing on past and recent clinical trials including the RIGHT 702 study, which identified the safest and most efficacious hydroxyurea dose...
  29. ncbi APC-targeted immunization for the treatment of HIV-1
    Franco Lori
    Research Institute for Genetic and Human Therapy, IRCCS Policlinico S Matteo, Pavia, Italy
    Expert Rev Vaccines 3:S189-98. 2004
    ..Exciting results have been obtained in nonhuman primates with both ex vivo and topical antigen-presenting cell-based therapeutic immunization...
  30. ncbi Quantification of HIV-specific CD8 T cells by in vitro stimulation with inactivated viral particles
    Jianqing Xu
    Research Institute for Genetic and Human Therapy (RIGHT, Washington, DC 20007, USA
    AIDS 16:1849-57. 2002
    ..Upon clinical validation, the CD8VIR assay can be a new diagnostic tool to predict the control of viral load rebound after treatment interruption...
  31. ncbi Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus-infected dendritic cells and lymphocytes
    Giampiero Piccinini
    Research Institute for Genetic and Human Therapy, IRCCS Policlinico S. Matteo, Pavia, Italy
    J Virol 76:2274-8. 2002
    ..A new criterion for combining drugs for the treatment of HIV infection could be to include at least one drug that selectively targets HIV in viral reservoirs...
  32. ncbi Therapeutic vaccination for future management of HIV/AIDS
    Julianna Lisziewicz
    Research Institute for Genetic and Human Therapy RIGHT, 2233 Wisconsin Avenue NW Suite 503, Washington, DC 20007, USA
    Vaccine 21:620-3. 2003
    ....
  33. ncbi High efficiency lentiviral gene delivery in non-dividing cells by deoxynucleoside treatment
    Elisabetta Ravot
    Research Institute for Genetic and Human Therapy (RIGHT) at IRCCS Policlinico San Matteo, Pavia, Italy
    J Gene Med 4:161-9. 2002
    ..This simple approach might be transferred to a broader range of quiescent cell types that are scarcely susceptible to lentiviral-based gene delivery due to low dNTP levels...
  34. ncbi Vaccinia assay for the rapid detection of functional HIV-specific CD8+ cytotoxic T lymphocytes
    Jianqing Xu
    Research Institute for Genetic and Human Therapy (RIGHT, Washington, DC, USA
    J Immunol Methods 276:45-57. 2003
    ..The recombinant vaccinia-based assay is a rapid, sensitive and quantitative test and is thus suitable for the detection of functional antigen-specific CD8(+) CTL in large-scale clinical studies...
  35. ncbi 2nd International Symposium on Molecular Diagnostics and Skin Gene Therapy
    Julianna Lisziewicz
    Research Institute for Genetic and Human Therapy, 2233 Wisconsin Ave, NW, Suite 503, Washington, DC 20007, USA
    Expert Opin Biol Ther 3:683-7. 2003
    ..Many scientific challenges facing this young field of medicine were presented, but there was also much discussion of ethical, regulatory and safety issues with respect to gene therapy...
  36. ncbi Stopping HAART temporarily in the absence of virus rebound: exploring new HIV treatment options
    Franco Lori
    aResearch Institute for Genetic and Human Therapy RIGHT at Fondazione IRCCS Policlinico S Matteo, Pavia, Italy and Bethesda, Maryland, USA bGenetic Immunity, Budapest, Hungary and Washington, DC, USA
    Curr Opin HIV AIDS 2:14-20. 2007
    ..Temporary interruptions of HAART in combination with therapeutic vaccinations and immune modulators, such as antiproliferative drugs, may suppress HIV for extended periods of time...
  37. ncbi HIV DART 2004--frontiers in drug development for antiretroviral therapies. 12-16 December 2004, Montego Bay, Jamaica
    Franco Lori
    Research Institute for Genetic and Human Therapy, 2233 Wisconsin Avenue NW, Suite 503, Washington, DC 20009, USA
    IDrugs 8:97-9. 2005